CliffBio
biologic

Entyvio

vedolizumab

Loss of exclusivityMay 2026projected — 12-year biologic exclusivity estimate
CompanyTakeda Pharmaceuticals U.S.A., Inc.

Drug detail

Brand nameEntyvio
Active ingredientvedolizumab
Strength300MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalMay 2014
Marketing statusRx

More from Takeda Pharmaceuticals U.S.A., Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Entyvio patent cliff — loss of exclusivity May 2026 | CliffBio